Log in to search using one of your social media accounts:

 

Alcohol linked to an increased risk of skin cancer
Conclusion These findings should be interpreted with care before concluding that an alcoholic drink per day increases your risk of skin cancer. There are several important cautions: These are only observational studies. It wouldn't be possible to randomise people to different alcohol intake and follow them to look at cancer development. And with observational studies, many other health, sociodemographic and lifestyle factors may be influencing the link between alcohol intake and cancer development. The studies differed considerably in terms of the influencing factors they took account of, with some adjusting for various ...
Source: NHS News Feed - August 7, 2017 Category: Consumer Health News Tags: Cancer Source Type: news

Alcohol increases the risk of skin cancer by up to 11%
Researchers from Brown University found that for every 10 grams of alcohol a day, a person's risk of basal cell carcinoma increases by 7 percent and cutaneous squamous cell carcinoma by 11 percent. (Source: the Mail online | Health)
Source: the Mail online | Health - August 1, 2017 Category: Consumer Health News Source Type: news

Alcohol intake may increase risk of nonmelanoma skin cancers
(Wiley) In a recent analysis of published studies, higher alcohol intake was linked with an increased risk of both basal cell carcinoma and cutaneous squamous cell carcinoma, which are nonmelanoma skin cancers. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - July 31, 2017 Category: International Medicine & Public Health Source Type: news

The Best Tx for Fungal Keratitis: Ophthalmology Times
(MedPage Today) -- Also, a new therapy for basal cell carcinoma nevus syndrome (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - June 27, 2017 Category: Hematology Source Type: news

Four presentations of skin conditions
The presentation, diagnosis and management of cutaneous infection with Mycobacterium chelonae, basal cell carcinoma, leiomyosarcoma and disseminated superficial actinic porokeratosis. (Source: GP Online Education)
Source: GP Online Education - June 13, 2017 Category: Primary Care Tags: 15.10 Skin Problems Source Type: news

Skin cancer on the rise
New diagnoses for two types of skin cancer increased in recent years, according to a team of researchers. Their paper uses medical records from the Rochester Epidemiology Project to compare diagnoses of basal cell carcinoma and squamous cell carcinoma ? both nonmelanoma skin cancers ? between 2000 and 2010 to diagnoses in prior years. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - May 15, 2017 Category: Science Source Type: news

Novel, Immune Therapies Promising in Nonmelanoma Skin Cancers
Treatment of keratinocyte carcinomas such as basal cell carcinoma and cutaneous squamous cell carcinoma with PD-1 checkpoint inhibitors and targeted agents warrant further investigation, according to recently published studies. (Source: CancerNetwork)
Source: CancerNetwork - March 9, 2017 Category: Cancer & Oncology Authors: Ian Ingram Tags: News Skin Cancer (Nonmelanoma) Source Type: news

Hugh Jackman's cancer and the dangers explained
The 48-year-old actor has been vocal about his battle with basal cell carcinoma since doctors spotted his first abnormal mole in 2013. So what is BCC, and why does Jackman's case keep returning? (Source: the Mail online | Health)
Source: the Mail online | Health - February 15, 2017 Category: Consumer Health News Source Type: news

Explained - Hugh Jackman's cancer
The 48-year-old actor has been vocal about his battle with basal cell carcinoma since doctors spotted his first abnormal mole in 2013. So what is BCC, and why does Jackman's case keep returning? (Source: the Mail online | Health)
Source: the Mail online | Health - February 14, 2017 Category: Consumer Health News Source Type: news

Hugh Jackman Urges Followers to Wear Sunscreen After Skin Cancer Scare
The Australian actor shared a personal photo after his treatment for basal cell carcinoma. Here's what you need to know about the condition. (Source: WebMD Health)
Source: WebMD Health - February 14, 2017 Category: Consumer Health News Source Type: news

Hugh Jackman Shares Photo After Having Another Basal Cell Carcinoma Removed
Hugh Jackman revealed Monday that he underwent more treatment for skin cancer. The star uploaded a photo to Instagram and Twitter after having another basal cell carcinoma removed from his nose. Basal cell carcinoma is the most frequently occurring form of cancer, according to the Skin Cancer Foundation. It is usually treatable, though, if not treated promptly, the SCF warns “it can be disfiguring.”  “Thanks to frequent body checks and amazing doctors, all is well. Looks worse with the dressing on than off. I swear! #wearsunscreen,” the “Logan” star captioned the photo.  ...
Source: Healthy Living - The Huffington Post - February 14, 2017 Category: Consumer Health News Source Type: news

SkinVision Unveils Breakthrough Algorithm that Takes the Fight to Skin Cancer
Dutch mobile health startup SkinVision has revealed its new algorithm that can detect most common forms of deadly skin cancer. Previously focused on detecting melanoma skin cancer, the app can now identify Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC) too, the first app ever to do that. (Source: eHealth News EU)
Source: eHealth News EU - January 27, 2017 Category: Information Technology Tags: Featured Industry Business and Industry Source Type: news

FDA: Topical Chemo Drug Lethal to Pets (FREE)
By Amy Orciari Herman Edited by Andr é Sofair, MD, MPH, and William E. Chavey, MD, MS Fluorouracil cream (USP 5%), used to treat actinic keratoses and basal cell carcinoma, … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - January 19, 2017 Category: Primary Care Source Type: news

Tattoos mark the spot for surgery, then disappear
Tattoos aren't just for body art. They can have medical applications, too. Doctors are using them on patients to mark an area for future treatment -- particularly for non-melanoma skin cancer such as basal cell carcinoma -- but the inks can cause problems. Now scientists have developed a better solution. In a new article, they report a new ink that glows only under certain light conditions and can disappear altogether after a period of time. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - December 21, 2016 Category: Science Source Type: news

Tattoos mark the spot -- for surgery -- then disappear
(American Chemical Society) Tattoos aren't just for body art. They can have medical applications, too. Doctors are using them on patients to mark an area for future treatment -- particularly for non-melanoma skin cancer such as basal cell carcinoma -- but the inks can cause problems. Now scientists have developed a better solution. In the journal ACS Nano, they report a new ink that glows only under certain light conditions and can disappear altogether after a period of time. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 21, 2016 Category: Global & Universal Source Type: news

Skin cream shows promise in treating basal cell carcinoma
Amy WallacePHILADELPHIA, Dec. 13 (UPI) -- Imiquimod skin cream was found to help boost the body's immune response to basal cell carcinoma and may alleviate the need for surgery in some patients. (Source: Health News - UPI.com)
Source: Health News - UPI.com - December 13, 2016 Category: Consumer Health News Source Type: news

Topical skin cream for treatment of basal cell carcinoma shows promise as an alternative to surgery
For basal cell carcinoma, an initial treatment success has been realized with imiquimod, which appears to be sustained over a five-year period, report researchers. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - December 13, 2016 Category: Science Source Type: news

Topical skin cream for treatment of basal cell carcinoma shows promise as an alternative to surgery
(Elsevier Health Sciences) A new study published in the Journal of Investigative Dermatology examines the effectiveness of imiquimod, a topical skin cream used to treat low-risk BCC lesions, over a five-year period. Investigators found that imiquimod success rates were sustained for the extended study period and did not promote lesion reoccurrence. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 13, 2016 Category: Global & Universal Source Type: news

PellePharm announces launch to develop topical gel for basal cell carcinoma
PellePharm announced its launch today, with financing from BridgeBio Pharma. The Menlo Park, Calif.-based company is developing a topical gel to treat basal cell carcinoma, including the tumors that result from Gorlin syndrome. The company’s topical inhibitor compound, patidegib, acts on the hedgehog pathway – a signaling pathway that transmits cellular information for adult tissue maintenance. Abnormal hedgehog signaling has been correlated with a number of cancers including basal cell carcinoma. PellePharm is studying the topical formulation of patidegib in 2 phase II trials. A study evaluating the gel’...
Source: Mass Device - December 8, 2016 Category: Medical Equipment Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Oncology Pharmaceuticals BridgeBio Pharma PellePharm Source Type: news

Vitamin D Intake Associated With Basal Cell Carcinoma Risk
Oral vitamin D intake was associated with an increased risk for basal cell carcinoma, but not melanoma, according to two large cohort studies. (Source: CancerNetwork)
Source: CancerNetwork - September 4, 2016 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Melanoma News Skin Cancer (Nonmelanoma) Source Type: news

Featured Reviews: August 2016
An overview of the featured Cochrane Reviews for   August 2016.Featured Review: Interventions to reduce corruption in the health sectorScarce evidence, but pointers to promising strategies to fight corruption in health care. Featured Review: Interventions for preventing abuse in theelderlyLack of good research on which programs or strategies are useful in preventing or reducing elder abuse.   Featured Review: Music interventions for improving psychological and physical outcomes in cancer patientsAre there benefits of offering music interventions as a complementary treatment to people with cancer?&n...
Source: Cochrane News and Events - August 25, 2016 Category: Information Technology Authors: mumoquit at cochrane.org Source Type: news

Featured Review: Sun protection to prevent basal cell carcinoma and cutaneous squamous cell carcinoma of the skin
One randomised trial has been done to date that compares different ways of using sunscreen and physical barrier methods to protect against common non-melanoma skin cancers. The quality of evidence to date is low but the review team urge caution in changing behaviour on the basis of the review findings.Keratinocyte cancer is a more common but less serious type of skin cancer than melanoma. It comprises basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC). The main risk factor for keratinocyte cancer is exposure to ultraviolet radiation, which is a component of sunlight. The incidence of this type of cance...
Source: Cochrane News and Events - August 10, 2016 Category: Information Technology Authors: mumoquit at cochrane.org Source Type: news

Is Early Detection of Basal Cell Carcinoma Worthwhile? Is Early Detection of Basal Cell Carcinoma Worthwhile?
Could earlier detection of basal cell carcinoma reduce morbidity and health care costs? This review examines whether BCC fulfills the World Health Organization criteria for preventive screening.The British Journal of Dermatology (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - August 8, 2016 Category: Pathology Tags: Hematology-Oncology Journal Article Source Type: news

HedgePath reports positive interim data from Phase IIb trial of SUBA-Itraconazole to treat Gorlin Syndrome
US-based, clinical stage biopharmaceutical company HedgePath (HPPI) has reported positive interim data from its Phase IIb clinical trial of SUBA-Itraconazole to treat basal cell carcinoma nevus syndrome (BCCNS), also known as Gorlin Syndrome. (Source: Drug Development Technology)
Source: Drug Development Technology - August 3, 2016 Category: Pharmaceuticals Source Type: news

Giant Basal Cell Carcinoma of the Scalp Giant Basal Cell Carcinoma of the Scalp
A patient presents with a fungating giant basal cell carcinoma of the scalp. How was this tumor excised and reconstructed? ePlasty, Open Access Journal of Plastic Surgery (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - July 21, 2016 Category: Pathology Tags: Hematology-Oncology Journal Article Source Type: news

Giant Basal Cell Carcinoma of the ScalpGiant Basal Cell Carcinoma of the Scalp
A patient presents with a fungating giant basal cell carcinoma of the scalp. How was this tumor excised and reconstructed? ePlasty, Open Access Journal of Plastic Surgery (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 21, 2016 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Where did it all go wrong? Scientists identify 'cell of origin' in skin cancers
Scientists have identified for the first time the 'cell of origin' -- in other words, the first cell from which the cancer grows -- in basal cell carcinoma, the most common form of skin cancer, and followed the chain of events that lead to the growth of these invasive tumors. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - July 8, 2016 Category: Science Source Type: news

Where did it all go wrong? Scientists identify 'cell of origin' in skin cancers
(University of Cambridge) Scientists have identified for the first time the 'cell of origin' -- in other words, the first cell from which the cancer grows -- in basal cell carcinoma, the most common form of skin cancer, and followed the chain of events that lead to the growth of these invasive tumors. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 8, 2016 Category: Cancer & Oncology Source Type: news

After skin cancer surgery, careful reconstruction around eyes and nose
Treatment Terms Plastic and reconstructive surgery Skin cancers Additional SEO Keywords skin cancer surgery, basal cell carcinoma SEO Meta Description Facial reconstruction helped Elizabeth Ann Badgett return to normal after Mohs surgery to remove basal skin cancer from her lower eyelid, cheek and nose. Overview For six months, Elizabeth Ann Badgett, of Clayton, NC, watched a painless, scaly spot appear and disappear on her nose. Each time the spot returned it was larger, until it reached the corner of her left eye. Her primary care doctor referred her to a dermatologist, who dia...
Source: dukehealth.org: Duke Health News - June 21, 2016 Category: Consumer Health News Authors: Anonymous Source Type: news

Topical skin creams effective to treat superficial basal cell carcinoma: New study
(Elsevier) Basal cell carcinoma is one of the most common cancers and its incidence is increasing worldwide, putting a significant burden on health services. Topical treatments are available for superficial basal cell carcinoma (BCC) but there has a lack of long-term follow-up data to guide treatment decisions. A three-year randomized controlled clinical trial has found that two topical creams are effective in most primary, low-risk superficial BCC, comparing favorably with photodynamic therapy (PDT). (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 2, 2016 Category: Cancer & Oncology Source Type: news

Vismodegib in basal cell carcinoma: Added benefit not proven
(Institute for Quality and Efficiency in Health Care) The drug manufacturer presented no suitable data after expiry of the limitation period. A study on the comparator therapy, which was not presented, raised doubts about the added benefit of vismodegib. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 27, 2016 Category: Global & Universal Source Type: news

Matrilin-2 protein distinguished BCCs from benign tumors in study
ORLANDO – Matrilin-2 – a matrix protein found in peritumoral stroma – reliably distinguished invasive basal cell carcinoma from the often difficult-to-distinguish basaloid follicular hamartoma (BFH), in a study that evaluated the protein as a marker in this setting. The protein marked 41 of 42... (Source: Skin and Allergy News)
Source: Skin and Allergy News - May 23, 2016 Category: Dermatology Source Type: news

FDA approves Biofrontera’s drug-device combo for sun-induced skin cancer
Biofrontera (ETR:B8F) shares are up today after the said it won pre-market approval from the FDA for its drug-device combination treatment for a type of sun-induced skin cancer. Leverkusen, Germany-based Biofrontera said the approval covers its Ameluz drug and BF-RhodoLED medical device for what it calls “photodynamic therapy” to treat mild to moderate actinic keratosis of the face and scalp. Also known as solar keratosis, actinic keratosis is caused by damage to the skin by the sun’s ultraviolet rays. The Biofrontera treatment uses the Ameluz gel, which contains a photo-activated compound ...
Source: Mass Device - May 13, 2016 Category: Medical Equipment Authors: Brad Perriello Tags: Drug-Device Combinations Food & Drug Administration (FDA) Oncology Regulatory/Compliance Biofrontera Source Type: news

EZH2 potential target in cutaneous basal cell carcinoma
The expression of the histone methyltransferase EZH2 correlates with aggressive subtypes of cutaneous basal cell carcinoma, highlighting the possibility that EZH2 may be an actionable target in this malignancy, say researchers. (Source: MedWire News)
Source: MedWire News - April 15, 2016 Category: Consumer Health News Tags: Oncology Source Type: news

Two new drugs equally effective against common skin cancer
Stephen FellerPHOENIX, March 31 (UPI) -- Two drugs, Vismodegib and Sonidegib, were found to be equally effective against basal cell carcinoma, according to researchers. (Source: Health News - UPI.com)
Source: Health News - UPI.com - March 31, 2016 Category: Consumer Health News Source Type: news

Scientists issue report advances in basal cell carcinoma
A new report details how two relatively new drugs are helping patients with basal cell carcinoma. Basal cell carcinoma is the most common type of skin cancer, producing nearly 2.8 million new cases annually in the US, and sunny Arizona has one of the world's highest incidences of skin cancer. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - March 31, 2016 Category: Science Source Type: news

TGen and Mayo Clinic scientists issue report in Cell on advances in basal cell carcinoma
(The Translational Genomics Research Institute) An article in the journal Cell by top scientists from the Translational Genomics Research Institute (TGen) and Mayo Clinic in Arizona details how two relatively new drugs are helping patients with basal cell carcinoma. Basal cell carcinoma is the most common type of skin cancer, producing nearly 2.8 million new cases annually in the US, and sunny Arizona has one of the world's highest incidences of skin cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 31, 2016 Category: Cancer & Oncology Source Type: news

Head and neck tumours: illustrated
Presentations of head and neck tumours including basal cell carcinoma and squamous cell carcinoma. (Source: GP Online Education)
Source: GP Online Education - March 7, 2016 Category: Primary Care Tags: 12 Care of People with Cancer and Palliative Care Source Type: news

Skin cancer: To each tumor its particularities, to each tumor its treatment
(Université de Genève) 90 percent of the population are at risk to develop a skin cancer, called basal cell carcinoma, one day. Although common, this cancer is rarely fatal and has until now been little studied. But geneticists sequenced the DNA of these skin tumors, in order to determine the genes that are responsible for the cancerogenesis. Their discovery of new cancer genes that cause BCC can pave the way for new treatment methods personalized for each tumor. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 7, 2016 Category: Cancer & Oncology Source Type: news

Anti-TNF therapy linked to ‘modest’ extra SCC risk
A Swedish population-based study shows that treatment with tumour necrosis factor inhibitors significantly increases the risk of developing squamous cell carcinoma, but not basal cell carcinoma, in patients with rheumatoid arthritis. (Source: MedWire News)
Source: MedWire News - February 11, 2016 Category: Consumer Health News Tags: Oncology Source Type: news

Organ transplant recipients face increased risk of BCC
Recipients of a solid organ transplant face up to a sixfold increase in the risk of developing a basal cell carcinoma – a risk that seems to increase as time passes. A pretransplant history of squamous cell carcinoma (SCC) increased this risk to 55 times that seen in the general population, Dr.... (Source: Skin and Allergy News)
Source: Skin and Allergy News - January 31, 2016 Category: Dermatology Source Type: news

New EMA Advice for PML Prevention With Fingolimod in MSNew EMA Advice for PML Prevention With Fingolimod in MS
The European Medicines Agency recommends evaluating patients for progressive multifocal leukoencephalopathy and for basal cell carcinoma before and during treatment with fingolimod (Gilenya). News Alerts (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - December 19, 2015 Category: Neurology Tags: Neurology & Neurosurgery News Alert Source Type: news

Higher risk of basal cell carcinoma linked to menopausal hormone therapy
Late age of natural menopause and use of menopausal hormone therapy were associated with significantly increased risk of basal cell carcinoma (BCC), according to results of a large, nationwide cohort study. Women who experienced menopause at age 55 years or later, compared with age 50-54 years,... (Source: Skin and Allergy News)
Source: Skin and Allergy News - November 2, 2015 Category: Dermatology Source Type: news

VivoSight OCT scanner significantly improves early-stage diagnosis of basal cell carcinoma
(Halsin Partners) Recent data shows that the VivoSight OCT scanner significantly improves diagnosis of basal-cell carcinoma at an earlier stage and reduces diagnostic biopsies by 36 percent. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 20, 2015 Category: Cancer & Oncology Source Type: news

Bree Towner has drastic surgery to re-build her face using skin from her scalp
WARNING GRAPHIC CONTENT: Bree Towner, 28, from Illinois, was diagnosed with a skin cancer called basal cell carcinoma. She lost the tip of her nose and now has to shave the new grafted one. (Source: the Mail online | Health)
Source: the Mail online | Health - October 2, 2015 Category: Consumer Health News Source Type: news

Vismodegib, Radiotherapy Promising in Recurrent Advanced BCCVismodegib, Radiotherapy Promising in Recurrent Advanced BCC
Two case might set the stage for the concurrent use of vismodegib and radiotherapy in recurrent advanced basal cell carcinoma (BCC). Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 17, 2015 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Sonidegib (Odomzo) Approved for Basal Cell Carcinoma in EUSonidegib (Odomzo) Approved for Basal Cell Carcinoma in EU
The new drug is approved for patients with locally advanced basal cell carcinoma who are not amenable to curative therapy or radiation. News Alerts (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - August 20, 2015 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

Odomzo (sonidegib) for the Treatment of Locally Advanced Basal Cell Carcinoma
Odomzo® (sonidegib) is an oral, selective smoothened (SMO) inhibitor indicated for the treatment of adult patients with locally advanced basal cell carcinoma (laBCC). The drug was discovered and developed by Novartis. (Source: Drug Development Technology)
Source: Drug Development Technology - July 29, 2015 Category: Pharmaceuticals Source Type: news

Medical News Today: FDA approve new daily pill for common skin cancer
The FDA have approved a new drug - sonidegib - for treating locally advanced basal cell carcinoma, an increasingly common cancer that occurs in the top layer of the skin. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - July 27, 2015 Category: Consumer Health News Tags: Melanoma / Skin Cancer Source Type: news

Odomzo Approved for Recurring Basal Cell Carcinoma
Title: Odomzo Approved for Recurring Basal Cell CarcinomaCategory: Health NewsCreated: 7/24/2015 12:00:00 AMLast Editorial Review: 7/27/2015 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - July 27, 2015 Category: Cancer & Oncology Source Type: news